Methotrexate Toxicity: When a Cancer Drug Stops Leaving the Body

Part of the ICU Emergencies Hub — browse every related guide in one place.

High-dose methotrexate is one of the few chemotherapy protocols where the antidote is scheduled before the first symptom appears. That inversion — treatment and rescue running on the same clock — is what makes it a critical-care problem rather than a purely oncologic one. When clearance fails, an ICU nurse is often the person watching the methotrexate level refuse to fall, and the interventions that follow are time-sensitive and level-driven.

The Mechanism: A Folate Roadblock

Methotrexate is a folate antagonist. It binds dihydrofolate reductase, the enzyme that keeps folate in its active, usable form. Without active folate, cells cannot make the building blocks for DNA, so any tissue that divides rapidly — bone marrow, the lining of the gut, and the developing blood cells — grinds to a halt. In malignancy that is the therapeutic effect. The toxicity is the same mechanism spilling onto healthy dividing tissue: myelosuppression, mucositis, and gastrointestinal injury, plus a distinct and dangerous kidney injury that feeds back into even higher drug levels.

The kidney injury deserves special attention because it is the engine of a vicious cycle. Methotrexate and its metabolites are poorly soluble in acidic urine. When urine is concentrated or acidic, the drug crystallizes in the renal tubules, injures the kidney, and reduces the very clearance the patient depends on. Less clearance means a higher blood level, which means more crystal deposition — a spiral that can convert a routine high-dose cycle into life-threatening toxicity within a day or two.

Leucovorin Rescue: Timed to the Level, Not the Clock Alone

Leucovorin (folinic acid) is already-active folate. It bypasses the enzyme methotrexate has blocked and re-supplies healthy cells with what they need to keep dividing, "rescuing" them from the folate blockade. Crucially, leucovorin rescue is not a fixed course you finish and forget — it is titrated against measured methotrexate levels drawn at set intervals after the infusion. As long as the methotrexate level remains elevated, leucovorin continues and often escalates; it is stopped only when the level falls below a defined threshold.

The other half of the equation is the methotrexate level itself. Levels are drawn on a protocol schedule (commonly at defined hours post-infusion), and each result dictates the next leucovorin dose and whether clearance is on track. A level that is higher than expected at a given time point is the early signal of delayed clearance — the warning that toxicity is developing before the counts or the creatinine have moved.

Hydration and Urine Alkalinization: Keeping the Drug Dissolved

Because methotrexate crystallizes in acidic urine, two supportive measures run continuously during and after a high-dose infusion: brisk IV hydration to keep urine dilute and flowing, and urinary alkalinization (typically with sodium bicarbonate) to raise urine pH into a range where the drug stays soluble. The nurse monitors urine pH at the bedside and titrates bicarbonate to keep it above the protocol target, and tracks urine output to confirm the kidney is still moving fluid.

Falling urine output, a rising creatinine, or a urine pH that keeps drifting acidic despite bicarbonate are all signals that clearance is failing. These are the moments to escalate — not to wait for the next scheduled level. The connection to acute kidney injury is direct: methotrexate nephrotoxicity is both a cause and a consequence of poor clearance, and protecting the kidney is protecting the patient.

Glucarpidase: The Rescue for the Rescue

When methotrexate levels remain dangerously high despite hydration, alkalinization, and leucovorin — usually in the setting of established kidney injury — there is a specific enzyme antidote: glucarpidase. Glucarpidase is a recombinant enzyme that cleaves methotrexate in the bloodstream into inactive metabolites, rapidly dropping the plasma concentration independent of the kidney. It is reserved for toxic, delayed-clearance situations because it directly removes the circulating drug the injured kidney can no longer clear.

The Interactions That Turn a Dose Lethal

Methotrexate toxicity is frequently precipitated by drug interactions that either reduce clearance or displace the drug. NSAIDs, certain antibiotics (notably some penicillins and sulfonamides), proton pump inhibitors, and probenecid can all raise methotrexate levels by competing for the same renal transporters or reducing kidney function. A patient who has cleared previous cycles fine can suddenly develop delayed clearance because a new NSAID or antibiotic was added. Reviewing the medication list for these interactions is a genuine safety intervention, not a formality.

The Bottom Line

High-dose methotrexate is a controlled poisoning with a scheduled antidote, and toxicity is fundamentally a story of failed clearance: an injured or acidic kidney lets the drug climb while the marrow and gut take the damage. The nurse holds three levers — hydration and alkalinization to keep the drug dissolved and moving, leucovorin timed precisely to the measured level, and early recognition of delayed clearance so glucarpidase can be given before the counts collapse. The single most useful instinct is to treat a methotrexate level that will not fall, or a urine pH that will not rise, as an emergency in motion rather than a lab value to recheck later.

Related: Acute kidney injury & CRRT | Tumor lysis syndrome | Hemodialysis & CRRT | Lab values guide